{"id":"W4399324904","doi":"10.1200/jco.2024.42.16_suppl.2013","title":"A phase II trial of olaparib and durvalumab in patients with recurrent IDH-mutated gliomas.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre; University Health Network; Princess Margaret Cancer Centre","funders":"Fondation Brain Canada","keywords":"Medicine; Durvalumab; Olaparib; Oncology; Internal medicine; Cancer research; Cancer; Genetics; Gene; Immunotherapy; Poly ADP ribose polymerase; Nivolumab","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008183869,0.00111179,0.001185783,0.0002653555,0.0002107978,0.0006383799,0.0005372656,0.0006974294,0.003200274],"category_scores_gemma":[0.0006370398,0.0003874796,0.0007557682,0.00026773,0.0004618706,0.0005220743,0.0002262043,0.001712986,0.0007610252],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008728261,"about_ca_system_score_gemma":0.0009264687,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000810823,"about_ca_topic_score_gemma":0.002457677,"domain_scores_codex":[0.9997573,0.0001111869,0.00001390325,0.00004156193,0.00002358733,0.00005233492],"domain_scores_gemma":[0.9997045,0.00004813681,0.0000587771,0.00002065133,0.00001684564,0.0001510541],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8340108,0.02153063,0.00408085,0.0005970786,0.0009937033,0.0003430686,0.0001900307,0.001611164,0.01673565,0.0003262222,0.004276621,0.115304],"study_design_scores_gemma":[0.8322916,0.1547853,0.00616285,0.00002796956,0.0003045583,0.0003712802,0.00004821313,0.001350054,0.001638006,0.0002494971,0.002751377,0.00001918205],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920065,0.002291091,0.000335756,0.0006385029,0.0001623314,0.001593263,0.0009409053,0.00007758055,0.001954036],"genre_scores_gemma":[0.9915285,0.001470837,0.0009788106,0.0007083637,0.0001214057,0.001442784,0.001696395,0.00001685735,0.002036003],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003200274,"threshold_uncertainty_score":0.01070595,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1119713020771566,"score_gpt":0.5119855964718868,"score_spread":0.4000142943947301,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}